Abeona and Lurie Children's Bring Hope with ZEVASKYN Therapy
ZEVASKYN marks a significant advancement in the treatment of recessive dystrophic epidermolysis bullosa (RDEB), offering a beacon of hope to patients suffering from this painful skin condition. Abeona Therapeutics, in collaboration with Ann & Robert H. Lurie Children’s Hospital of Chicago, proudly announces the launch of ZEVASKYN, the first and only cell-based gene therapy now available commercially in the U.S. for this disorder.
Understanding ZEVASKYN and Its Impact
RDEB is a rare genetic disorder notable for causing severe and painful skin wounds due to defects in the COL7A1 gene. These wounds not only cause discomfort but can also lead to serious complications affecting overall health and life quality. ZEVASKYN, with its gene-modified cellular sheets, represents a transformative approach by incorporating functional type VII collagen into a patient's skin cells to promote healing and provide lasting relief.
Collaboration at Its Best
With the activation of Lurie Children’s as the first Qualified Treatment Center (QTC) for ZEVASKYN, the hospital is now poised to embark on the treatment of patients affected by RDEB. Dr. Madhav Vasanthavada, the Chief Commercial Officer at Abeona, emphasizes the importance of this activation, indicating not only a significant step in patient care but also highlighting the deep-rooted partnership with Lurie Children's, which is celebrated for its expertise in genetic skin disorders.
A Holistic Support System for Patients
Abeona’s commitment extends beyond treatment with the introduction of Abeona Assist™, a comprehensive patient care program dedicated to guiding eligible patients and their families through their ZEVASKYN treatment journey. This program aims to alleviate concerns regarding insurance coverage, financial support, and logistical arrangements, ensuring families have the resources they need for successful outcomes.
The Journey to ZEVASKYN's Approval
The journey toward ZEVASKYN's approval was marked by immense effort and scientific innovation. Approved by the U.S. Food and Drug Administration (FDA), this therapy provides a unique one-time treatment option for patients, eliminating the need for repeated interventions. Furthermore, Lurie Children's has been at the forefront of treating complex genetic skin disorders for over three decades, making this collaboration even more impactful as they leverage their extensive experience and resources.
What Makes ZEVASKYN Unique?
The uniqueness of ZEVASKYN lies in its application and the science behind it. Unlike conventional treatments that may only manage symptoms, this therapy seeks to heal by addressing the root cause of RDEB. Patients receiving ZEVASKYN undergo a transformative process where their skin cells are modified to carry the COL7A1 gene, which is essential for skin integrity. As a result, this therapy promises a new horizon for those suffering from chronic wounds, offering long-term healing and a significant reduction in pain.
The Future of Gene Therapy at Lurie Children’s
As Lurie Children’s continues to be a leader in gene therapy, ZEVASKYN stands out as their tenth gene therapy offering, showcasing their dedication towards tackling various genetic disorders. The hospital’s comprehensive Gene and Cellular Medicine Program works tirelessly to advance therapies that benefit children suffering from conditions that previously had limited treatment options.
Patient Resources and Safety Information
Understanding that safety is paramount, specific guidelines and safety measures accompany every ZEVASKYN treatment. Patients are advised of potential allergic reactions and the importance of continuous monitoring following treatment to ensure there are no complications. Common side effects, though generally manageable, also require attention to safeguard patient health throughout their recovery.
Engaging with the Community
Abeona Therapeutics and Lurie Children’s are not only dedicated to treating patients but are also committed to engaging with the community. They encourage discussions and inquiries about ZEVASKYN through various channels, including emails and direct contact options. Both organizations share a vision for a world where patients with RDEB can thrive without the limitations of their condition.
Frequently Asked Questions
What is ZEVASKYN?
ZEVASKYN is an innovative cell therapy designed to treat wounds in patients suffering from recessive dystrophic epidermolysis bullosa (RDEB), using gene-modified cellular sheets.
How does ZEVASKYN work?
The therapy integrates functional type VII collagen into a patient’s skin cells, facilitating better wound healing and pain reduction in affected areas.
Who can receive ZEVASKYN treatment?
Both adults and pediatric patients diagnosed with RDEB are eligible to receive ZEVASKYN, provided they meet the necessary health criteria outlined by treatment centers.
Where can patients receive treatment?
Currently, Lurie Children’s Hospital is the first Qualified Treatment Center where patients can begin their ZEVASKYN treatment journey.
What support services are offered?
Abeona Assist™ provides personalized support throughout the treatment process, including assistance with insurance and logistical concerns, making sure patients and families receive comprehensive care.
